New hope for Tough-to-Treat breast cancer: trial tests Immune-Boosting combo
NCT ID NCT04759248
Summary
This study is testing a new three-drug combination for people with advanced HER2-positive breast cancer that has stopped responding to standard treatments. It combines an immunotherapy drug (atezolizumab) with two established cancer drugs (trastuzumab and vinorelbine). The goal is to see if this combination can better control the cancer and extend life for patients who have few options left.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Complejo Hospitalario Universitario A Coruña (CHUAC)
A Coruña, La Coruña, 15006, Spain
-
H. Clínico San Cecilio de Granada
Granada, Andalusia, Spain
-
Hospital Clinic de Barcelona
Barcelona, Spain
-
Hospital Clinico Universitario de Valencia
Valencia, Spain
-
Hospital General Universitario de Alicante
Alicante, Spain
-
Hospital San Pedro de Alcántara
Cáceres, Spain
-
Hospital Son Espases
Palma de Mallorca, Spain
-
Hospital Universitari Sant Joan de Reus
Reus, 43201, Spain
-
Hospital Universitari Vall d' Hebron
Barcelona, Spain
-
Hospital Universitario 12 de octubre
Madrid, Spain
-
Hospital Universitario Virgen del Rocio
Seville, Spain
-
Hospital Universitario de Canarias
Santa Cruz de Tenerife, Canary Islands, 38320, Spain
-
Hospital de León
León, 24071, Spain
-
Hospital del Mar
Barcelona, Barcelona, 08003, Spain
-
Institut Català d'Oncologia Hospitalet
L'Hospitalet de Llobregat, Barcelona, Spain
Conditions
Explore the condition pages connected to this study.